VivaVision

VivaVision was established in August 2016 as an innovative pharmaceutical company. Since its inception, the company has focused on developing internationally leading innovative drugs for the treatment of ophthalmic diseases, committed to providing better and superior therapeutic options for millions of patients with eye conditions. VivaVision boasts a world-class ophthalmology team and has established a leading product R&D pipeline. Its pipeline candidate, VVN001, is currently in clinical trials, while other products targeting ocular surface and fundus diseases are under development at various stages. Since its establishment, VivaVision has become one of the most leading innovative ophthalmic drug R&D companies in China.